A Clinical Brexanolone Treatment Program at an Academic Medical Center- challenges and lessons learned with patient selection and post 30 day outcomes.

Autor: Patterson, Riah, Krohn, Holly, Richardson, Erin, Kimmel, Mary, Meltzer-Brody, Samantha
Zdroj: Journal of the Academy of Consulation-Liason Psychiatry; 20210101, Issue: Preprints
Abstrakt: Brexanolone (Zulresso) is the first Federal Drug Administration (FDA) approved drug for the treatment of postpartum depression (PPD). Brexanolone is a positive allosteric modulator of the GABAAreceptor, and is given over 60 hours by infusion in a medical setting. This drug has been shown to be effective at significantly reducing Hamilton Rating Scale for Depression (HAM-D) scores at 60 hours and 30 days post-infusion, however data beyond 30 days have not yet been available. There have been limited clinical programs able to offer brexanolone due to the complexity of setting up this treatment in a medical setting.
Databáze: Supplemental Index
Externí odkaz: